NUVASIVE, INC. (NASDAQ:NUVA) Files An 8-K Financial Statements and Exhibits

NUVASIVE, INC. (NASDAQ:NUVA) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.

99.1 Press release issued by NuVasive, Inc. on September7, 2017
Story continues below

EX-99.1 2 d100006dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   NEWS RELEASE NUVASIVE ANNOUNCES ACQUISITION OF VERTERA SPINE NuVasive invests in advanced materials science portfolio with first-of-its-kind porous PEEK technology SAN DIEGO,…
To view the full exhibit click here


Nuvasive, Inc. is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The Company’s biologics product line offerings includes allograft (donated human tissue), FormaGraft (a collagen synthetic product), Osteocel Plus and Osteocel Pro (each an allograft cellular matrix containing viable mesenchymal stem cells (MSCs)), and AttraX (a synthetic bone graft material), all of which are used to aid the spinal fusion or bone healing process.

An ad to help with our costs